この開示の添付ファイルは以下です：
MIRA Pharmaceuticals | 3: Initial statement of beneficial ownership of securities-Director Whalen Matthew Pratt
ミラ・ファーマシューティカルズ | 3：インサイダー登録報告書-取締役 Whalen Matthew Pratt
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
注目ニュース
更新日時